Christopher Nardo

Christopher Nardo

Corporate Officer/Principal at DERMATA THERAPEUTICS, INC.

Net worth: 708 $ as of 2024-03-30

59 year
Health Technology
Consumer Services

Profile

Christopher J.
Nardo
is currently the Chief Development Officer & Senior VP at Dermata Therapeutics, Inc. He previously worked as the Senior Director-Clinical Development at Allergan, Inc. from 2010 to 2015 and as the Vice President-Clinical Operations & Biostatistics at Spectrum Pharmaceuticals, Inc. from 2005 to 2010.
Dr. Nardo holds a graduate degree from San Diego State University, an undergraduate degree from Loyola Marymount University, and a doctorate degree from The University of North Carolina at Chapel Hill.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-03-19 1,722 ( 0.03% ) 708 $ 2024-03-30

Christopher Nardo active positions

CompaniesPositionStart
DERMATA THERAPEUTICS, INC. Corporate Officer/Principal 2015-05-31
All active positions of Christopher Nardo

Former positions of Christopher Nardo

CompaniesPositionEnd
ALLERGAN, INC. Corporate Officer/Principal 2014-12-31
SPECTRUM PHARMACEUTICALS, INC. Corporate Officer/Principal 2009-12-31
See the detail of Christopher Nardo's experience

Training of Christopher Nardo

San Diego State University Graduate Degree
Loyola Marymount University Undergraduate Degree
The University of North Carolina at Chapel Hill Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Christopher Nardo's experience

Connections

73

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
SPECTRUM PHARMACEUTICALS, INC.

Health Technology

DERMATA THERAPEUTICS, INC.

Health Technology

Private companies1

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Christopher Nardo
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW